Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi Sells 5,423 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 5,423 shares of Sight Sciences stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $2.78, for a total value of $15,075.94. Following the completion of the transaction, the chief technology officer now directly owns 1,744,118 shares in the company, valued at $4,848,648.04. This trade represents a 0.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

David Badawi also recently made the following trade(s):

• On Wednesday, January 8th, David Badawi sold 3,829 shares of Sight Sciences stock. The stock was sold at an average price of $3.26, for a total transaction of $12,482.54.
• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The shares were sold at an average price of $3.52, for a total value of $10,950.72.

Sight Sciences Stock Performance

Shares of SGHT stock opened at $2.89 on Wednesday. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36. Sight Sciences, Inc. has a 52 week low of $2.67 and a 52 week high of $8.45. The company’s fifty day simple moving average is $3.59 and its two-hundred day simple moving average is $5.35.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The company had revenue of $20.16 million during the quarter, compared to analyst estimates of $20.41 million. As a group, research analysts predict that Sight Sciences, Inc. will post -1.01 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of SGHT. KCK LTD. purchased a new stake in shares of Sight Sciences in the 4th quarter worth approximately $15,925,000. Long Focus Capital Management LLC lifted its holdings in Sight Sciences by 86.9% during the second quarter. Long Focus Capital Management LLC now owns 560,594 shares of the company’s stock worth $3,739,000 after buying an additional 260,594 shares during the period. B. Riley Wealth Advisors Inc. purchased a new position in shares of Sight Sciences in the 2nd quarter valued at $1,234,000. Millrace Asset Group Inc. bought a new position in shares of Sight Sciences in the 3rd quarter worth $874,000. Finally, State Street Corp lifted its stake in shares of Sight Sciences by 17.4% during the 3rd quarter. State Street Corp now owns 646,776 shares of the company’s stock worth $4,075,000 after purchasing an additional 95,843 shares during the last quarter. Institutional investors own 55.51% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on SGHT shares. UBS Group began coverage on shares of Sight Sciences in a research note on Friday, December 6th. They set a “buy” rating and a $5.50 target price for the company. Piper Sandler reissued a “neutral” rating and issued a $5.50 target price (down from $6.00) on shares of Sight Sciences in a report on Friday, November 8th. Morgan Stanley lowered their price target on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research report on Monday, November 11th. Lake Street Capital decreased their target price on shares of Sight Sciences from $5.00 to $3.00 and set a “hold” rating for the company in a report on Wednesday, January 15th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a research note on Tuesday, January 14th. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Sight Sciences presently has a consensus rating of “Hold” and a consensus price target of $4.72.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.